The rising prevalence of obesity - impacting over 650 million adults globally - has accelerated the development of oral pharmaceutical therapies as alternatives to injectable treatments. Among these, GLP-1 receptor agonists are gaining traction in oral dosage formats due to their potential for improved patient adherence and broader accessibility.
The successful formulation of all oral obesity molecules depends heavily on excipient selection. Excipients are critical to ensuring manufacturability, stability, bioavailability, and patient acceptability of the final dosage form. Their role becomes even more pivotal when addressing the unique challenges associated with high-dose, moisture-sensitive, or modified-release drug candidates.
Why Excipients Matter in Obesity Drug Development
Excipients are the unsung heroes of oral dosage forms. While the active pharmaceutical ingredient (API) delivers the therapeutic effect, excipients ensure that the medication is manufacturable, stable, and easy for patients to take. In the context of obesity treatments, where long-term adherence and global accessibility are critical, the right excipient strategy can make all the difference.
Here’s how Colorcon’s excipient offerings support the development of effective and scalable oral obesity therapies, including GLP-1's:
- Starch 1500®, Partially Pregelatinized Maize Starch: offers exceptionally low water activity, making it ideal for stabilizing moisture-sensitive drugs. It supports excellent content uniformity and promotes efficient disintegration and dissolution. Suitable for dry compression without the need for heat or added moisture, it helps minimize peptide degradation, and when paired with protective agents, may also function as a carrier matrix for stabilized peptides.
- StarTab®, Directly Compressible Starch: is purposefully designed to simplify formulation and processing through direct compression. It provides outstanding flowability and mechanical strength, key attributes for high-speed tablet production and efficient downstream packaging of small molecule drugs.
- StarCap®, Superior-Flow Maize Starch: is a partially pregelatinized excipient known for its exceptional flow characteristics, ensuring clean and efficient capsule filling. It serves as both a diluent and disintegrant, while also contributing to the stability of reactive drug compounds.
- SUGLETS® Sugar Spheres: are uniform sucrose-starch pellets ideal for sustained or extended-release multiparticulate formulations. With low friability, precise sphericity, tight particle size control, and high batch consistency, they’re optimized for drug layering.
Premium Quality Hypromellose Polymers for Exceptional Formulations
Colorcon’s AnyCoat hypromellose (HPMC) polymers offer a proven solution for achieving excellent development and manufacturing efficiency across immediate, delayed, and controlled release dosage forms.- HPMC for Tablets and Capsules: AnyCoat-C high viscosity formulations are widely utilized as a wet binder in high shear and fluid bed granulation, providing enhanced tablet and granule strength, and supporting controlled drug release. Additionally, it serves as a high-performance film-forming and gelling agent for capsule production.
- HPMC for Solutions and Suspensions: AnyCoat-C low viscosity formulations substantially increase liquid viscosity, exhibiting an exponential rise with concentration. Its dual hydrophilic and hydrophobic nature makes it an effective suspending agent, well-suited for creating stable solutions and suspensions.
Final Thoughts
With the rise of oral formulations in obesity drug development, excipients are proving essential to delivering therapies that are not only effective but also scalable, stable, and patient friendly. Coloron’s excipient technologies are designed to meet the unique challenges of these formulations — supporting better outcomes for patients and accelerating time-to-market for developers. Additionally, our proprietary excipient blending capabilities are a key part of that advantage. Ask us how we can support your next custom excipient formulation.
In future posts, we’ll explore how our film coatings and packaging innovations further enhance oral obesity formulations.